Literature DB >> 25305251

Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.

Delphine Peaureaux1, Beatrice Pignolet2, Damien Biotti1, Florence Bucciarelli2, Jana Gaina1, Cristina Bucur1, Michel Clanet2, Guillaume Martin-Blondel3, David Brassat4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25305251     DOI： 10.1177/1352458514549823

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  2 in total

1.  Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Authors:  Luisa Klotz; Berit Grützke; Maria Eveslage; Michael Deppe; Catharina C Gross; Lucienne Kirstein; Anita Posevitz-Fejfar; Tilman Schneider-Hohendorf; Nicholas Schwab; Sven G Meuth; Heinz Wiendl
Journal:  BMC Neurol       Date:  2015-06-23       Impact factor: 2.474

2.  Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased?

Authors:  Jin Nakahara; Laura Tomaske; Kodai Kume; Tadayuki Takata; Masaki Kamada; Kazushi Deguchi; Kenji Kufukihara; Ruth Schneider; Ralf Gold; Ilya Ayzenberg
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-04-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.